TME-SW
01698
XIAOMI-W
01810
BOSS ZHIPIN-W
02076
TENCENT
00700
JD HEALTH
06618
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Cash flow from operating activities | ||||||||||
Earning before tax | 26.90%434M | 4.98%654M | -6.04%342M | -17.04%623M | -11.00%364M | 118.31%751M | 209.85%409M | 109.10%344M | -5.04%132M | -684.02%-3.78B |
Profit adjustment | ||||||||||
Investment loss (gain) | 37.04%-17M | -57.89%-30M | -200.00%-27M | -18.75%-19M | 0.00%-9M | 23.81%-16M | 35.71%-9M | 41.67%-21M | 53.33%-14M | 2.70%-36M |
Impairment and provisions: | ---- | 173.33%164M | ---- | -15.49%60M | ---- | 455.00%71M | --3M | -100.58%-20M | ---- | 1,130.11%3.43B |
-Impairment of property, plant and equipment (reversal) | ---- | --163M | ---- | ---- | ---- | 133.33%7M | ---- | -99.69%3M | ---- | --958M |
-Other impairments and provisions | ---- | -98.33%1M | ---- | -6.25%60M | ---- | 378.26%64M | --3M | -100.93%-23M | ---- | 786.74%2.47B |
Revaluation surplus: | 366.67%40M | -95.65%1M | -350.00%-15M | -46.51%23M | -89.29%6M | --43M | --56M | ---- | ---- | 28.10%155M |
-Other fair value changes | 366.67%40M | -95.65%1M | -350.00%-15M | -46.51%23M | -89.29%6M | --43M | --56M | ---- | ---- | 28.10%155M |
Asset sale loss (gain): | ---- | ---- | ---- | ---- | ---- | 100.00%6M | -125.00%-1M | -99.01%3M | 140.00%4M | --302M |
-Loss (gain) from sale of subsidiary company | ---- | ---- | ---- | ---- | ---- | 500.00%6M | ---- | -99.67%1M | ---- | --302M |
-Loss (gain) on sale of property, machinery and equipment | ---- | ---- | ---- | ---- | ---- | ---- | -150.00%-1M | --2M | --2M | ---- |
-Loss (gain) from selling other assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 120.00%2M | ---- |
Depreciation and amortization: | 38.39%1.17B | 44.60%1.9B | 30.45%844M | 64.91%1.32B | 83.81%647M | 32.12%798M | 18.12%352M | -0.49%604M | -2.93%298M | 9.76%607M |
Financial expense | 3.95%1.11B | 31.90%2B | 53.61%1.06B | 36.40%1.51B | 13.26%692M | 0.00%1.11B | 7.38%611M | -10.41%1.11B | -8.52%569M | -6.07%1.24B |
Special items | 64.41%-21M | -240.00%-136M | -168.18%-59M | 89.80%-40M | 92.47%-22M | -262.96%-392M | -1,436.84%-292M | -800.00%-108M | 52.50%-19M | 78.95%-12M |
Operating profit before the change of operating capital | 26.12%2.71B | 30.95%4.55B | 28.01%2.15B | 46.65%3.48B | 48.63%1.68B | 24.01%2.37B | 16.39%1.13B | 0.21%1.91B | -0.61%970M | 12.50%1.91B |
Change of operating capital | ||||||||||
Accounts receivable (increase)decrease | -473.71%-2.39B | 170.98%1.03B | 155.86%639M | 147.02%379M | -566.94%-1.14B | -458.22%-806M | 406.25%245M | 111.45%225M | 91.21%-80M | -35.80%-1.97B |
Accounts payable increase (decrease) | 77.34%1.08B | -32.78%-1.05B | 434.21%609M | -68.16%-787M | 110.71%114M | 28.44%-468M | -185.25%-1.06B | -136.52%-654M | ---373M | 1,727.55%1.79B |
Cash from business operations | -58.75%1.4B | 47.77%4.54B | 424.07%3.4B | 179.76%3.07B | 109.03%648M | -26.03%1.1B | -40.04%310M | -14.48%1.48B | 64.65%517M | 399.71%1.73B |
Other taxs | -37.63%-128M | -23.81%-208M | -20.78%-93M | -51.35%-168M | -71.11%-77M | -65.67%-111M | -60.71%-45M | -26.42%-67M | -47.37%-28M | -65.63%-53M |
Net cash from operations | -61.46%1.27B | 49.16%4.33B | 478.46%3.3B | 194.22%2.9B | 115.47%571M | -30.37%986M | -45.81%265M | -15.76%1.42B | 65.76%489M | 374.86%1.68B |
Cash flow from investment activities | ||||||||||
Interest received - investment | 23.68%47M | 96.97%65M | 111.11%38M | -63.74%33M | -76.32%18M | 184.38%91M | 484.62%76M | -15.79%32M | -58.06%13M | -47.22%38M |
Loan receivable (increase) decrease | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 400.00%30M | ---- | -102.53%-10M |
Sale of fixed assets | ---- | ---- | ---- | ---- | ---- | ---- | --1M | ---- | ---- | 733.33%25M |
Purchase of fixed assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 44.53%-284M | ---- | 77.06%-512M |
Sale of subsidiaries | ---- | ---- | ---- | ---- | ---- | -117.86%-5M | ---- | -91.91%28M | ---- | --346M |
Acquisition of subsidiaries | 83.48%-210M | -86.43%-2.58B | -598.35%-1.27B | 30.02%-1.39B | 83.10%-182M | -1,470.63%-1.98B | -1,582.81%-1.08B | -2,420.00%-126M | 34.69%-64M | 97.62%-5M |
Recovery of cash from investments | ---- | ---- | ---- | --4M | ---- | ---- | ---- | ---- | ---- | ---- |
Cash on investment | -251.41%-6.85B | -104.18%-15B | 43.21%-1.95B | -56.59%-7.35B | -956.00%-3.43B | -411.11%-4.69B | -48.40%-325M | ---918M | 36.71%-219M | ---- |
Other items in the investment business | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 300.00%4M | --3M | ---2M |
Net cash from investment operations | -120.36%-7.01B | -101.47%-17.52B | 11.51%-3.18B | -32.04%-8.7B | -171.40%-3.6B | -433.63%-6.59B | -396.25%-1.33B | -928.33%-1.23B | -94.89%-267M | 94.68%-120M |
Net cash before financing | -4,842.98%-5.74B | -127.67%-13.19B | 104.00%121M | -3.48%-5.79B | -185.38%-3.03B | -3,176.37%-5.6B | -577.48%-1.06B | -88.34%182M | 40.51%222M | 182.03%1.56B |
Cash flow from financing activities | ||||||||||
New borrowing | 38.96%17.93B | 86.12%43.81B | 54.63%12.9B | 45.15%23.54B | 59.65%8.35B | 152.82%16.22B | 19.50%5.23B | 81.19%6.41B | 126.05%4.37B | -59.69%3.54B |
Refund | 22.11%-12.09B | -131.01%-34.73B | -201.79%-15.53B | -64.12%-15.03B | -53.72%-5.15B | -129.03%-9.16B | -14.39%-3.35B | 7.49%-4B | -13.32%-2.93B | 30.42%-4.32B |
Issuing shares | ---- | ---- | ---- | ---- | ---- | -79.97%320M | -79.97%320M | 215.19%1.6B | 141.39%1.6B | --507M |
Issuance of bonds | --2.3B | --3.5B | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Interest paid - financing | -7.20%-1.1B | -32.45%-1.94B | -56.71%-1.03B | -51.24%-1.46B | -22.85%-656M | -13.35%-968M | -45.90%-534M | 17.73%-854M | 29.21%-366M | -2.06%-1.04B |
Dividends paid - financing | -45.65%-201M | -230.17%-591M | -45.26%-138M | -96.70%-179M | ---95M | ---91M | ---- | ---- | ---- | ---- |
Absorb investment income | -32.05%1.32B | 111.60%2.12B | --1.95B | -66.67%1B | ---- | --3B | --3.01B | ---- | ---- | ---- |
Issuance expenses and redemption of securities expenses | ---409M | -233.33%-20M | ---- | 99.41%-6M | ---- | 69.31%-1.02B | 71.96%-516M | -789.87%-3.34B | -5,011.11%-1.84B | 13.99%-375M |
Pledged bank deposit (increase) decrease | 162.77%494M | 227.78%2.18B | -1,224.29%-787M | -416.51%-1.71B | -80.77%70M | -61.91%539M | -52.60%364M | 1,041.13%1.42B | 304.21%768M | 117.71%124M |
Other items of the financing business | ---- | ---- | ---- | ---- | ---- | 290.91%42M | 650.00%30M | -83.33%-22M | 125.00%4M | 72.73%-12M |
Net cash from financing operations | 403.05%8.05B | 132.58%14.18B | -206.20%-2.66B | -31.24%6.1B | -44.67%2.5B | 629.71%8.87B | 181.92%4.52B | 176.27%1.22B | 530.03%1.6B | -337.05%-1.59B |
Effect of rate | -17.02%39M | -135.88%-47M | 0.00%47M | 536.67%131M | 154.65%47M | 49.15%-30M | -120.51%-86M | 56.62%-59M | -230.00%-39M | -402.22%-136M |
Net Cash | 191.21%2.31B | 226.82%987M | -384.89%-2.54B | -90.76%302M | -115.11%-523M | 133.86%3.27B | 89.59%3.46B | 4,465.63%1.4B | 949.30%1.83B | 97.40%-32M |
Begining period cash | 18.14%6.19B | 8.99%5.25B | 8.79%5.24B | 205.26%4.81B | 205.26%4.81B | 559.83%1.58B | 559.83%1.58B | -41.28%239M | -41.28%239M | -74.45%407M |
Cash at the end | 210.74%8.54B | 17.91%6.19B | -36.65%2.75B | 8.99%5.25B | -12.42%4.34B | 205.26%4.81B | 144.47%4.95B | 559.83%1.58B | 812.61%2.03B | -41.28%239M |
Cash balance analysis | ||||||||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | -- | -- | -- |
Auditor | -- | Grant Thornton (Hong Kong) Certified Public Accountants Limited | -- | Grant Thornton (Hong Kong) Certified Public Accountants Limited | -- | Grant Thornton (Hong Kong) Certified Public Accountants Limited | -- | Grant Thornton (Hong Kong) Certified Public Accountants Limited | -- | Grant Thornton (Hong Kong) Certified Public Accountants Limited |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.